Viking Therapeutics(VKTX)2025-04-23 20:05Financial Performance - Viking reported a net loss of 0.41 per share, for Q1 2025, compared to a net loss of 0.26 per share, in Q1 2024[16]. - Net loss for Q1 2025 was 27,356,000 in Q1 2024, representing a 67.0% increase in losses year-over-year[25]. - Basic and diluted net loss per share for Q1 2025 was 0.26 in Q1 2024, reflecting a 57.7% increase in loss per share[25]. - Weighted-average shares used to compute basic and diluted net loss per share increased to 112,069,000 in Q1 2025 from 103,457,000 in Q1 2024, an increase of 8.3%[25]. Expenses - Research and development expenses increased to 24.1 million in Q1 2024, primarily due to higher manufacturing costs and clinical studies[14]. - Total operating expenses for Q1 2025 were 34,073,000 in Q1 2024[25]. - General and administrative expenses rose to 10.0 million in Q1 2024, mainly due to increased legal and patent service costs[15]. - Research and development expenses for Q1 2025 were 24,103,000 in Q1 2024, representing a 71.9% increase[25]. - General and administrative expenses rose to 9,970,000 in Q1 2024, marking a 41.1% increase[25]. Cash Position and Assets - Viking ended Q1 2025 with a strong cash position of 903 million at the end of 2024[17]. - Cash and cash equivalents increased to 26,676,000 at the end of 2024, reflecting a 42.3% increase[27]. - Total assets decreased to 908,321,000 at December 31, 2024, a decline of 4.5%[27]. - Total liabilities decreased to 28,043,000 at December 31, 2024, a reduction of 28.4%[27]. - The accumulated deficit increased to 487,907,000 at the end of 2024, indicating a rise of 9.3%[27]. Clinical Development - Phase 3 trials for subcutaneous VK2735 are expected to begin in Q2 2025, following positive results from the Phase 2 VENTURE study[5][6]. - The Phase 2 VENTURE-Oral Dosing trial for VK2735 in obesity has been fully enrolled with approximately 280 subjects, and data is expected in the second half of 2025[11]. - VK2735 demonstrated statistically significant weight loss of up to 14.7% in the Phase 2 VENTURE study after 13 weeks of treatment[6]. - Viking's DACRA program aims to target obesity and is advancing with in vivo data presented at the 2024 ADA Annual Scientific Sessions[11]. - The company plans to file an IND for its dual amylin and calcitonin receptor agonist program in the second half of 2025[12]. Manufacturing and Agreements - Viking entered into a broad manufacturing agreement with CordenPharma to support the commercialization of VK2735, securing dedicated capacity for multiple metric tons of API annually[12].